Aethlon Medical INC 10-Q quarterly reports

Aethlon Medical's Q1 2026 Form 10-Q filing details ongoing clinical development for its Hemopurifier, continued net losses, and a recent capital raise.

Aethlon Medical, Inc. reported its Q3 2026 financial results, highlighting progress in its Australian oncology trial and a recent capital raise, while facing ongoing liquidity concerns.

Aethlon Medical reported reduced net losses and advanced its Hemopurifier oncology trial in Australia, while addressing Nasdaq listing compliance and acknowledging ongoing capital needs.

Aethlon Medical, a clinical-stage medical device company, reported a significant cash reduction and issued a going concern warning, despite progress in its Australian oncology trial.

Aethlon Medical's Q3 2025 report details ongoing clinical trials for the Hemopurifier, recent equity transactions, and financial results, while acknowledging the need for additional funding.

Aethlon Medical reports a net loss of $5.37 million for the six months ended September 30, 2024, while advancing clinical trials for its Hemopurifier device.

Aethlon Medical's Q1 2025 report shows reduced operating expenses and a successful capital raise, alongside progress in clinical trial approvals for their Hemopurifier device.

Aethlon Medical's Q3 2024 report reveals increased operating expenses and net losses, alongside ongoing efforts to advance clinical trials and address manufacturing challenges.